loading page

Twice Neglected? Neglected Diseases in Neglected Populations
  • +1
  • Ethel Weld,
  • Catriona Waitt,
  • Karen Barnes ,
  • FACUNDO GARCIA-BOURNISSEN
Ethel Weld
Johns Hopkins University School of Medicine

Corresponding Author:eweld@jhmi.edu

Author Profile
Catriona Waitt
University of Liverpool Institute of Translational Medicine
Author Profile
Karen Barnes
Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
Author Profile
FACUNDO GARCIA-BOURNISSEN
National Research Council (CONICET)
Author Profile

Abstract

It is unfortunately true that clinicians lack the necessary evidence to know how to use medications properly in large sections of the population, and we do not have optimal drugs to use in many Neglected Tropical Diseases (NTDs). NTD’s often disproportionately affect neglected populations such as children and pregnant women. As reliable access to safe, effective preventives and treatments can break the cycle of poverty, illness, and ensuing debility that further perpetuates poverty, it is of paramount importance to investigate and develop new medicines for neglected populations suffering from NTDs. Furthermore, there is not only a need to develop and evaluate novel therapies, but also to ensure that these are affordable, available, and adapted to the communities who need them. With this editorial, the British Pharmacological Society hereby launches a call for high-quality articles focusing on NTDs in special populations, to facilitate the reversal of this dual neglect.
31 Aug 2021Submitted to British Journal of Clinical Pharmacology
01 Sep 2021Submission Checks Completed
01 Sep 2021Assigned to Editor
01 Sep 2021Reviewer(s) Assigned
15 Sep 2021Review(s) Completed, Editorial Evaluation Pending
23 Sep 2021Editorial Decision: Revise Minor
06 Oct 20211st Revision Received
07 Oct 2021Submission Checks Completed
07 Oct 2021Assigned to Editor
07 Oct 2021Review(s) Completed, Editorial Evaluation Pending
07 Oct 2021Editorial Decision: Accept
Feb 2022Published in British Journal of Clinical Pharmacology volume 88 issue 2 on pages 367-373. 10.1111/bcp.15148